Technology | October 08, 2012

FDA Grants CLIA-Waived Status to CoaguChek XS Plus System for INR Testing

Exemption of the system from virtually all CLIA rules gives more labs access to connectivity and data management capabilities for monitoring patients on warfarin therapy

CoaguChek XS Plus System Point of Care Testing Blood Testing

October 8, 2012 — The U.S. Food and Drug Administration (FDA) has granted Clinical Laboratory Improvement Amendments (CLIA)-waived status to the Roche CoaguChek XS Plus system. The point-of-care anticoagulation monitor offers connectivity and data management tools to help healthcare professionals manage PT/INR (blood clotting time) testing. The waiver means that the monitoring technology may now be used in a broader range of clinical settings, such as labs that do not meet the requirements to perform moderate- or high-complexity testing as defined by the CLIA of 1988.

"The waived status of CoaguChek XS Plus system allows healthcare professionals in CLIA-waived environments access to new tools and connectivity options to help them manage patients on warfarin therapy," said Rod Cotton, senior vice president, professional diagnostics, physician office laboratory, and medical and scientific affairs, at Roche Diagnostics Corporation. "The technology has several features that help ensure fast, accurate results, and the connectivity capabilities help healthcare providers with regulatory compliance, making it easier for them to manage their anticoagulation practices."

The CoaguChek XS Plus system offers the ability to connect and transfer data to IT solutions, including Telcor QML, Rals-Plus with expanded device configuration capabilities or through the POCT1A standard data transfer protocol. Implementing connectivity with the CoaguChek XS Plus enables data transfer and reporting capabilities to help hospital staff streamline the regulatory compliance process, capture reimbursable costs and improve their organizational efficiency.

The system uses two-level, built-in quality controls to help ensure the accuracy of PT/INR test results, but also offers optional liquid quality controls for facilities with policies requiring the use of external quality control measures.

For more information: www.roche.com or www.roche-diagnostics.us.

Related Content

FDA Clears Abbott's High Sensitivity Troponin-I Blood Test
Technology | Blood Testing | October 09, 2019
Abbott recently announced that its Architect Stat High Sensitivity Troponin-I blood test has received clearance from...
Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes
News | Blood Testing | September 18, 2019
Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high-sensitivity cardiac troponin T...
Validation Studies Confirm High Accuracy of Novel HART AI-Driven Blood Tests
News | Blood Testing | March 19, 2019
Prevencio Inc. announced data confirming the high accuracy of its artificial intelligence (AI)-driven, multiple-protein...
CoaguChek XS PT Test Strips Recalled for Inaccurately Reporting High INR
News | Blood Testing | December 28, 2018
Terrific Care LLC. / Medex Supply Dist Inc. initiated a nationwide recall on Dec. 19 of Roche CoaguChek test strips, as...
Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule